FY24 NPAT recovered 490% but H1 delivered NZ$28.1m of the NZ$30.7m
The reported rebound was front-loaded into the first half while capex tripled to NZ$54.9m and the announced dividend fell to 4.25c.
Published 22 April 2026
Read briefingSector archive
Browse recent results from companies in the same sector.
Showing 25-48 of 65 published briefings.
The reported rebound was front-loaded into the first half while capex tripled to NZ$54.9m and the announced dividend fell to 4.25c.
Published 22 April 2026
Read briefingHeadline 65% EBITDA gain and 16.6% revenue decline both reflect a portfolio change, while receivables ballooned $114m and the dividend was cut 64%.
Published 21 April 2026
Read briefingStrong $1.6b free cash flow funded a 15c special dividend on top of the 40c ordinary payout for FY24.
Published 22 April 2026
Read briefingA $7.7m non-cash biological-asset/inventory swing pulled GAAP earnings down even as volumes, revenue and the company's guided pro-forma measure
Published 23 April 2026
Read briefingEarnings rebounded from a cyclone-impacted base, but capex jumped 828% and net debt/EBITDA at 1.33x sits above its historical range.
Published 22 April 2026
Read briefingFY24 met the $43m EBITDA guide but H2 NPAT turned negative and the cash rebound was driven by a $17.4m working-capital release.
Published 21 April 2026
Read briefingApples drove the operating recovery, but tax distortion, a NZ$50.0m rise in net debt and weaker operating cash cloud the read.
Published 22 April 2026
Read briefingOperating deterioration plus a sharply higher tax rate left FY24 NPAT at $7.7m, well below the $17–22m underlying earnings guided at the half.
Published 18 May 2026
Read briefingNPAT looks 92.0% better on a tax swing while receivable days jumped 47 days and cash halved to $5.6m.
Published 23 April 2026
Read briefingEBITDA margin collapsed to an unprecedented 3.0% on a 15.2% revenue decline, leaving the balance sheet under acute refinancing pressure.
Published 23 April 2026
Read briefingReported NPAT of $28.5m is flattered by a $15.8m fair value uplift and cash conversion ran at just 28.1% as working capital absorbed $12.3m.
Published 22 April 2026
Read briefingWeather-driven volume damage pushed PBT to -$64.2m as gross borrowings rose 33.9% and equity fell 10.0%.
Published 22 April 2026
Read briefingA NZ$24.5m working-capital release lifted operating cash, but FCF pre-lease was still NZ$-20.1m and banking support was needed.
Published 23 April 2026
Read briefingA working-capital release flattered cash conversion to 120.5% and funded the increase, masking margin pressure from Cyclone Gabrielle.
Published 22 April 2026
Read briefingThe 13.1% PBT decline understates the result: operating cash flow dropped to $3.4m and the special dividend was funded from asset disposal, not
Published 18 May 2026
Read briefingCash conversion improved sharply but earnings power weakened, leverage rose to 2.6x net debt/EBITDA, and FY24 guidance trails FY23's $61.2m.
Published 22 April 2026
Read briefingA strong first half driven by record Brazil volumes is shadowed by a downward revision to US seedling sales in the heavier second half.
Published 23 April 2026
Read briefingContinuing operations swung to a $14.1m loss as a Dairyworks discontinued-operation gain partly cushioned reported NPAT.
Published 23 April 2026
Read briefingRecovery from the FY23 mortality event delivered a $36.4m EBITDA swing, but reported EBITDA of $18.5m sits well above pro-forma EBITDA of $10.7m.
Published 22 April 2026
Read briefingCash conversion collapsed from 38.8% to 12.3% in Seeka's seasonally strong half, with orchard and Australian operations swinging to losses.
Published 23 April 2026
Read briefingHeadline NPAT to shareholders fell 85.1% as the Horticulture segment swung from a NZ$15.2m profit to a NZ$2.1m loss after cyclone disruption.
Published 22 April 2026
Read briefingRevenue rose 18.6% to NZ$765.3m but PBT fell to negative NZ$21.4m as a cyclone-hit apples crop and net debt up 57% strained the balance sheet.
Published 22 April 2026
Read briefingPBT swung to US$0.9m and EBITDA rose 35%, but an unusually favourable working-capital release supplied most of the cash flow lift.
Published 23 April 2026
Read briefingFY23 NPAT guidance cut to a NZ$(5)m–NZ$5m range as inventory build pushes net debt/EBITDA to 10.04x and Advanced Nutrition demand softens.
Published 23 April 2026
Read briefingGet full NZX result briefings by email as new coverage is published.